Cellular agriculture scaling

UPSIDE Foods, GOOD Meat, Aleph Farms, Meatly LLC, Vivici and The EVERY Company are among the named commercial players. Their approaches vary: several develop cultivated meat, while Vivici and The EVERY Company use precision fermentation for dairy or egg proteins. Recent activity also includes facility commissioning, manufacturing partnerships and efforts to expand production capacity.

Tufts University, TU Munich, Nanjing Agricultural University and the National University of Singapore are active research organizations. FACTS lists 31 documents for Tufts University, 16 for Nanjing Agricultural University and 13 for the National University of Singapore in the 24-month window. Recent research addresses edible scaffolds, process modeling, tissue maturation and bioprocess engineering.

FACTS records $53.3 million in grants across 32 grants since 2020. It separately lists five funding rounds totaling $870.4 million, though those round records are not all clearly specific to cellular agriculture scale-up. Treat the grant and round figures as distinct funding indicators, rather than as a single directly comparable measure.

In June 2026, Vivici received $14.4 million through the European Innovation Council Accelerator to scale precision-fermented dairy proteins. In March 2026, Standing Ovation announced a $28.5 million Series B and an additional $5.7 million in non-dilutive funding for precision-fermented dairy proteins. These announcements indicate continued financing for ingredient-scale fermentation.

Ramot At Tel Avlv University Ltd is the only patent holder listed in FACTS, with 1 patent. That single listed holder should not be read as a complete measure of intellectual-property ownership across the field. The data also lists 23 patents overall, but patent activity in the recent 24-month window is limited.

FACTS lists 1 patent in the 24-month window and 23 patents overall, but does not provide a patent-growth percentage. Publication activity is more active: FACTS reports 71 publications in the latest year and 39.2% publication growth. This points to substantial research attention, while the available patent figures do not establish a rising patent trend.

Maturity is uneven: Meatly was commissioning a 20,000-liter production facility in September 2026, while recent research continues to address process models, media costs and tissue maturation. Precision-fermented proteins have also reached industrial production, according to a September 2026 publication. Commercial readiness therefore varies by product, process and production system.

The four approaches are suspension cell culture, microcarrier culture, structured tissue production and precision fermentation. Suspension culture grows cells in liquid; microcarriers supply surfaces for cells that need attachment. Structured tissue methods aim to form organized meat-like material, while fermentation uses microbes to produce target proteins. Each approach has distinct constraints around cell behavior, materials, processing or product structure.

The United States leads the country-level document counts in FACTS with 2,098 documents, followed by the United Kingdom with 759 and Germany with 581. These country counts are not mutually exclusive shares of a single global total. They indicate where related activity is recorded, rather than measuring production capacity or commercial market share.

FACTS identifies meat and poultry, seafood, dairy proteins, egg proteins and pet food as applications. It lists 651 documents for meat and poultry, 210 for dairy proteins, 116 for pet food, 84 for egg proteins and 61 for seafood. These document counts indicate areas of activity, not market size or commercial output.